编辑推荐——腹主动脉瘤腔内修复术后患者生存预测模型的外部验证
该多中心国际回顾性观察性队列研究纳入四个欧洲主动脉中心2001至2021年治疗的1500例腹主动脉瘤患者,外部验证基于年龄、eGFR和COPD的生存预测模型,中位随访65个月,54.6%患者死亡。
要点
- 模型外部验证区分度略降且校准有过拟合迹象,但可识别EVAR术后生存率低的高危亚组。
- 高危亚组5年和10年生存率分别仅55.2%和15.5%。
核心结论
- EVAR是腹主动脉瘤的有价值治疗选择,尤其对不适合开放修复的患者。
- 并非所有患者都能从EVAR获益,个体化治疗推荐应包括对预期寿命的考量。
- 本研究提供风险分层,以识别在当前直径阈值下可能无法从EVAR获益的患者。
研究设计与样本
- 多中心国际回顾性观察性队列研究,数据来自四个欧洲主动脉中心2001至2021年治疗的患者。
- 验证队列纳入1500例患者,中位随访65个月,期间54.6%的患者死亡。
- 初始模型纳入年龄、估算肾小球滤过率(eGFR)和慢性阻塞性肺疾病(COPD)作为生存的独立预测因子。
- 模型性能通过区分度和校准度评估。
主要发现
- 外部验证显示区分能力略降,校准显示过拟合迹象。
- 上述高危亚组5年和10年生存率分别仅55.2%和15.5%。
关键数值与推荐
- 当前指南推荐对小型无症状腹主动脉瘤进行直径监测,因破裂风险低。
- 男性直径≥5.5 cm、女性直径≥5.0 cm推荐择期腹主动脉瘤修复。
- 初始模型包括年龄、eGFR和COPD作为生存的独立预测因子。
临床怎么用
- 作者认为EVAR是腹主动脉瘤的有价值治疗选择,尤其对不适合开放修复的患者。
- 作者认为并非所有患者都能从EVAR获益,个体化治疗推荐应包括对预期寿命的考量。
- 作者指出本研究提供风险分层,以识别在当前直径阈值下可能无法从EVAR获益的患者。
局限性
- 外部验证显示区分能力略降,校准有过拟合迹象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current guidelines recommend diameter monitoring of small and asymptomatic abdominal aortic aneurysms (AAAs) due to the low risk of rupture. Elective AAA repair is recommended for diameters ≥ 5.5 cm in men and ≥ 5.0 cm in women. However, data supporting the efficacy of elective treatment for all patients above these thresholds are diverging. For a subgroup of patients, life expectancy might be very short, and elective AAA repair at the current threshold may not be justified. This study aimed to externally validate a predictive model for survival of patients with an asymptomatic AAA treated by endovascular aneurysm repair (EVAR). METHODS: This was a multicentre international retrospective observational cohort study. Data were collected from four European aortic centres treating patients between 2001 and 2021. The initial model included age, estimated glomerular filtration rate (eGFR), and chronic obstructive pulmonary disease (COPD) as independent predictors for survival. Model performance was measured by discrimination and calibration. RESULTS: The validation cohort included 1 500 patients with a median follow up of 65 months, during which 54.6% of the patients died. The external validation showed slightly decreased discrimination ability and signs of overfitting in model calibration. However, a high risk subgroup of patients with impaired survival rates was identified: octogenarians with eGFR < 60 OR COPD, septuagenarians with eGFR < 30, and septuagenarians with eGFR < 60 and COPD having survival rates of only 55.2% and 15.5% at five and 10 years, respectively. CONCLUSION: EVAR is a valuable treatment option for AAA, especially for patients unsuitable for open repair. Nonetheless, not all these patients will benefit from EVAR, and an individualised treatment recommendation should include considerations on life expectancy. This study provides a risk stratification to identify patients who may not benefit from EVAR using the present diameter thresholds.
引用
- Dabravolskaité V, Aweys MM, Venermo M, et al. Editor's Choice - External Validation of a Prognostic Model for Survival of Patients With Abdominal Aortic Aneurysms Treated by Endovascular Aneurysm Repair. Eur J Vasc Endovasc Surg. 2023. PMID: 37995960. doi:10.1016/j.ejvs.2023.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。